Tourmaline Bio Stock Today

TRML Stock   17.33  0.93  5.09%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Above Average

 
High
 
Low
Tourmaline Bio is selling for 17.33 as of the 19th of March 2025. This is a 5.09% down since the beginning of the trading day. The stock's lowest day price was 17.22. Tourmaline Bio has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of May 2021
Category
Healthcare
Classification
Health Care
Tourmaline Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 25.69 M outstanding shares of which 3.13 M shares are at this time shorted by private and institutional investors with about 10.57 trading days to cover. More on Tourmaline Bio

Moving together with Tourmaline Stock

  0.7ME 23Andme HoldingPairCorr
  0.7VANI Vivani Medical Earnings Call This WeekPairCorr

Moving against Tourmaline Stock

  0.87VALN Valneva SE ADRPairCorr
  0.77DMAC DiaMedica TherapeuticsPairCorr
  0.77VIGL Vigil NeurosciencePairCorr
  0.56EQ EquilliumPairCorr
  0.5VERV Verve TherapeuticsPairCorr
  0.45DVAX Dynavax TechnologiesPairCorr

Tourmaline Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO CoFounderSandeep MD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities9.4 M8.9 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total38 K40 K
Notably Down
Pretty Stable
Total Assets324.5 M309 M
Sufficiently Up
Slightly volatile
Total Current Assets282.3 M268.8 M
Sufficiently Up
Slightly volatile
Debt Levels
Tourmaline Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tourmaline Bio's financial leverage. It provides some insight into what part of Tourmaline Bio's total assets is financed by creditors.
Liquidity
Tourmaline Bio currently holds 244 K in liabilities. Note, when we think about Tourmaline Bio's use of debt, we should always consider it together with its cash and equity.

Depreciation

37,050
Tourmaline Bio (TRML) is traded on NASDAQ Exchange in USA. It is located in 27 West 24th Street, New York, NY, United States, 10010 and employs 74 people. Tourmaline Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 469.02 M. Tourmaline Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.69 M outstanding shares of which 3.13 M shares are at this time shorted by private and institutional investors with about 10.57 trading days to cover. Tourmaline Bio generates negative cash flow from operations
Check Tourmaline Bio Probability Of Bankruptcy
Ownership Allocation
Tourmaline Bio shows a total of 25.69 Million outstanding shares. The majority of Tourmaline Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tourmaline Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tourmaline Bio. Please pay attention to any change in the institutional holdings of Tourmaline Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly two million one hundred thirty-four thousand four hundred fifty-seven invesors are currently shorting Tourmaline Bio expressing very little confidence in its future performance.
Check Tourmaline Ownership Details

Tourmaline Bio Historical Income Statement

At this time, Tourmaline Bio's Other Operating Expenses is quite stable compared to the past year. Research Development is expected to rise to about 70.3 M this year, although the value of Gross Profit will most likely fall to (39.8 K). View More Fundamentals

Tourmaline Stock Against Markets

Tourmaline Bio Corporate Management

Susan JonesChief OfficerProfile
Kimberly PiorkowskiCulture PeopleProfile
Bradford JDGeneral OfficerProfile
Dr MBAChief OfficerProfile
Emil MDSenior ResearchProfile
Yung MDChief OfficerProfile
When determining whether Tourmaline Bio is a strong investment it is important to analyze Tourmaline Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tourmaline Bio's future performance. For an informed investment choice regarding Tourmaline Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.89)
Return On Assets
(0.22)
Return On Equity
(0.29)
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.